BNTXBioNTech SE

Nasdaq biontech.de


$ 93.14 $ -3.94 (-4.06 %)    

Tuesday, 28-May-2024 12:22:48 EDT
QQQ $ 454.82 $ 0.31 (0.07 %)
DIA $ 398.57 $ -0.80 (-0.21 %)
SPY $ 530.36 $ -0.42 (-0.08 %)
TLT $ 91.26 $ -0.74 (-0.81 %)
GLD $ 225.37 $ 0.49 (0.23 %)
$ 96.95
$ 97.08
$ 0.00 x 0
$ 0.00 x 0
$ 92.91 - $ 97.09
$ 85.21 - $ 125.83
1,245,252
na
23.05M
$ 0.08
$ 0.02
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jim-cramer-celestica-makes-a-comeback-sell-this-movie-theater-stock

Jim Cramer called Celestica Inc. "terrific" after the Toronto-based company reported better-than-expected first-quarter...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 reported-sunday-medilink-therapeutics-and-biontech-enhance-strategic-partnership-with-tmalin-adc-technology-collaboration

Under the terms of this new agreement, MediLink will receive an upfront payment of $25 million and is eligible to receive addit...

 moderna-was-among-the-best-performing-large-cap-stocks-last-week-may-20-may-26-2024-are-they-in-your-portfolio

Top-performing stocks last week were FSLR, MRNA, ELF, NVDA, IP, ADI, FLEX, LOGI, BNTX, and MNDY, boosted by positive news and a...

 hc-wainwright--co-reiterates-buy-on-biontech-maintains-113-price-target

HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.

 experts-predict-rise-in-covid-19-cases-vaccine-stocks-climb

Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covi...

Core News & Articles

https://www.nbcnews.com/now/video/disease-experts-predict-a-small-rise-in-covid-cases-this-summer-211393605953 Disease experts ...

 biontech-says-european-patent-offices-decision-to-maintain-modernas-patent-ep-no-3-590-949-b1-in-amended-form-does-not-change-cos-stance-on-patent-says-believe-that-neither-ep-949-nor-any-of-the-auxiliary-requests-filed-by-moderna-meet-the-requirements-for-patentability-says-will-continue-to-vigorously-defend-its-innovations-against-all-allegations-of-patent-infringement-including-ep-949-case

-Reuters

 european-patent-office-sides-with-moderna-in-covid-19-vaccine-patent-dispute-with-pfizerbiontech

Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents.

Core News & Articles

https://www.ft.com/content/50c5078c-c9f0-4b35-b916-3475b641c773Moderna has won a case at the European Patent Office in its disp...

 evercore-isi-group-initiates-coverage-on-biontech-with-in-line-rating-announces-price-target-of-100

Evercore ISI Group analyst Cory Kasimov initiates coverage on BioNTech (NASDAQ:BNTX) with a In-Line rating and announces Pri...

 elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

 hc-wainwright--co-maintains-buy-on-biontech-raises-price-target-to-113

HC Wainwright & Co. analyst Robert Burns maintains BioNTech (NASDAQ:BNTX) with a Buy and raises the price target from $1...

 td-cowen-maintains-hold-on-biontech-raises-price-target-to-98

TD Cowen analyst Yaron Werber maintains BioNTech (NASDAQ:BNTX) with a Hold and raises the price target from $95 to $98.

 bmo-capital-maintains-outperform-on-biontech-lowers-price-target-to-122

BMO Capital analyst Etzer Darout maintains BioNTech (NASDAQ:BNTX) with a Outperform and lowers the price target from $123 to...

 whats-going-with-biontech-stock-on-monday

BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by inn...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION